SCHEMBL14745517

SCHEMBL14745517

CCCC(=NCc1ccc(OC)cc1OC)c1ccc2c(c1)cc1n2CCN(C(=O)O)C1C(C)(C)C

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.35
SHMT2 P34897 1/20 0.35
KMT2A Q03164 6/20 0.33
MEN1 O00255 5/20 0.33
MAPT P10636 2/20 0.33
TP53 P04637 1/20 0.33
ALDH1A1 P00352 4/20 0.33
POLB P06746 2/20 0.33
TSHR P16473 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
MAPK1 P28482 1/20 0.33
RAB9A P51151 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
S1PR1 P21453 1/20 0.32
PLA2G4A P47712 1/20 0.32
KDM4E B2RXH2 1/20 0.32
PPARG P37231 1/20 0.32
MTNR1A P48039 1/20 0.32
MTNR1B P49286 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14745920 0.79 LMNA (0.37) LMNAKMT2AMEN1MAPTTP53
SCHEMBL14745921 0.79 LMNA (0.37) LMNAKMT2AMEN1MAPTTP53
SCHEMBL14745515 0.77 PDE4A (0.39) LMNAKMT2AMEN1MAPTTP53
SCHEMBL14741318 0.75 PDE4B (0.42) LMNAKMT2AMEN1MAPTTP53
SCHEMBL14744897 0.75 PDE4B (0.42) LMNAKMT2AMEN1MAPTTP53
SCHEMBL14744869 0.71 AADAT (0.35) KMT2AMEN1MAPTTP53ALDH1A1
SCHEMBL16428739 0.69 NPC1 (0.33) LMNAKMT2AMEN1MAPTTP53
SCHEMBL14741305 0.68 MAPT (0.32) LMNAKMT2AMEN1MAPTTP53
SCHEMBL16568046 0.67 MEN1 (0.41) LMNAKMT2AMEN1MAPTALDH1A1
SCHEMBL16568045 0.67 MEN1 (0.41) LMNAKMT2AMEN1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 US disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 US disclosed
EP-2750504-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033258-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP LMNA 2119/4885SHMT2 3254/4885KMT2A 4450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.